Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
67 hedge funds and large institutions have $86.2M invested in Antares Pharma, Inc. in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 14 closing their positions.
46% more capital invested
Capital invested by funds: $59.1M → $86.2M (+$27.1M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less funds holding
Funds holding: 71 → 67 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$744K |
| 2 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
+$594K |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$447K |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$426K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$365K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.83M |
| 2 |
WHI
William Harris Investors
Chicago,
Illinois
|
-$2.08M |
| 3 |
PLP
Pleasant Lake Partners
Rincon,
Puerto Rico
|
-$806K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$607K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$565K |
ATRS Hedge Fund Activity: Q3 2016 in Review
67 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2016, worth a combined $86.2M — up 46% from $59.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ATRS and 10 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 16 added.
The largest buyer was Perkins Capital Management, opening a new position worth an estimated $744K. The largest seller was Armistice Capital, cutting an estimated $3.83M.
- 67 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2016, down from 71 in Q2 2016.
- Funds reported $86.2M of Antares Pharma, Inc. stock for Q3 2016, up 46% quarter-over-quarter.
- 10 funds opened new Antares Pharma, Inc. positions in Q3 2016 and 14 closed out, a net change of -4 holders.
- The largest Antares Pharma, Inc. buyer in Q3 2016 was Perkins Capital Management, an estimated $744K added.
- The largest Antares Pharma, Inc. seller in Q3 2016 was Armistice Capital, an estimated $3.83M sold.
Based on aggregated 13F filings for Q3 2016.